Abbott Laboratories (NYSE: ABT) kicked off on Friday, down -1.43% from the previous trading day, before settling in for the closing price of $123.53. Over the past 52 weeks, ABT has traded in a range of $111.02-$141.23.
During the last 5-year period, the sales growth of Healthcare Sector giant was 29.98%. While this was happening, its average annual earnings per share was recorded 10.32%. With a float of $1.73 billion, this company’s outstanding shares have now reached $1.74 billion.
Abbott Laboratories (ABT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Abbott Laboratories is 0.67%, while institutional ownership is 80.62%. The most recent insider transaction that took place on Nov 25 ’25, was worth 203,043. In this transaction Senior Vice President of this company sold 1,586 shares at a rate of $128.02, taking the stock ownership to the 30,384 shares. Before that another transaction happened on Nov 25 ’25, when Company’s Officer proposed sale 1,586 for $128.02, making the entire transaction worth $203,042.
Abbott Laboratories (ABT) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 1.34 earnings per share (EPS), higher than consensus estimate (set at 1.34) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.33% during the next five years compared to 29.98% growth over the previous five years of trading.
Abbott Laboratories (NYSE: ABT) Trading Performance Indicators
Take a look at Abbott Laboratories’s (ABT) current performance indicators. Last quarter, stock had a quick ratio of 1.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.83. Likewise, its price to free cash flow for the trailing twelve months is 30.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.97, a number that is poised to hit 1.50 in the next quarter and is forecasted to reach 5.67 in one year’s time.
